Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

Surgical Oncology, Recist Guideline, Medicine +9

Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms

J. Gregory Caporaso, Christian L. Lauber, William A. Walters et al. · The ISME Journal · 2012 · 8.8K citations · Full text

Genetics, Miseq Platforms, Genomics +17

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.2K citations

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi et al. · Science · 2017 · 4.4K citations · Full text

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Ayelet Sivan, Leticia Corrales, Nathaniel Hubert et al. · Science · 2015 · 3.6K citations · Full text

Immune Evasion, Cancer Immunosurveillance, Ribosomal Rna +14